Results 11 to 20 of about 2,631,955 (205)

The importance of ancestry to understanding tumor mutation burden in cancer [PDF]

Cancer Cell, 2022
In the current issue of Cancer Cell, Nassar and colleagues find that in solid tumors, tumor-only sequencing leads to an overestimate of the biomarker tumor mutation burden (TMB), particularly in patients of African or Asian ancestry. Correction of the TMB estimate improves the correlation between TMB and response to immunotherapy.
Snyder, Alexandra, McGranahan, Nicholas
core   +5 more sources

Racial disparities in patient survival and tumor mutation burden, and the association between tumor mutation burden and cancer incidence rate [PDF]

Scientific Reports, 2017
AbstractThe causes underlying racial disparities in cancer are multifactorial. In addition to socioeconomic issues, biological factors may contribute to these inequities, especially in disease incidence and patient survival. To date, there have been few studies that relate the disparities in these aspects to genetic aberrations.
Zhang, Wensheng, Edwards, Andrea, Flemington, Erik K., Zhang, Kun   +3 more
core   +4 more sources

Tumor mutation burden: from comprehensive mutational screening to the clinic [PDF]

Cancer Cell International, 2019
The recent advent of immunomodulatory therapies into the clinic has demanded the identification of innovative predictive biomarkers to identify patients most likely to respond to immunotherapy and support the design of tailored clinical trials.
Francesca Galuppini, Carlo Alberto Dal Pozzo, Jutta Deckert, Fotios Loupakis, Matteo Fassan, Raffaele Baffa   +5 more
doaj   +4 more sources

Association of LRP1B Mutation With Tumor Mutation Burden and Outcomes in Melanoma and Non-small Cell Lung Cancer Patients Treated With Immune Check-Point Blockades [PDF]

Frontiers in Immunology, 2019
Background: Tumor mutation burden (TMB) have been served as the most prevalent biomarkers to predict immunotherapy response. LRP1B (low-density lipoprotein receptor-related protein 1B) is frequently mutated in melanoma, non-small cell lung cancer (NSCLC)
Hao Chen, Hao Chen, Wei Chong, Qian Wu, Yueliang Yao, Min Mao, Xin Wang   +6 more
doaj   +2 more sources

BLM mutation is associated with increased tumor mutation burden and improved survival after immunotherapy across multiple cancers

Cancer Medicine
Background BLM encodes a RecQ DNA helicase that regulates genomic stability, and its mutations are associated with increased cancer susceptibility. Here, we show a multifaceted role of BLM mutations in tumorigenesis and immunotherapy. Methods and Results:
Huiping Shi, Liang Gao, Hong Yin, Min Jiang   +3 more
doaj   +2 more sources

Tumor mutation burden and recurrent tumors in hereditary lung cancer [PDF]

Cancer Medicine, 2019
Lung cancer is the leading cause of cancer death worldwide and cancer relapse accounts for the majority of cancer mortality. The mechanism is still unknown, especially in hereditary lung cancer without known actionable mutations.
Yi‐Chiung Hsu, Ya‐Hsuan Chang, Gee‐Chen Chang, Bing‐Ching Ho, Shin‐Sheng Yuan, Yu‐Cheng Li, Jhih‐Wun Zeng, Sung‐Liang Yu, Ker‐Chau Li, Pan‐Chyr Yang, Hsuan‐Yu Chen   +10 more
doaj   +3 more sources

Very low mutation burden is a feature of inflamed recurrent glioblastomas responsive to cancer immunotherapy. [PDF]

, 2021
Several immunotherapy clinical trials in recurrent glioblastoma have reported long-term survival benefits in 10-20% of patients. Here we perform genomic analysis of tumor tissue from recurrent WHO grade IV glioblastoma patients acquired prior to ...
Verhaak, Roel G, Yan, Hai, Peters, Katherine B., Verhaak, Roel G., Lipp, Eric S., Sampson, John H., Wei, Zhi, Verhaak, Roel G W, Gromeier, Matthias, Beaubier, Nike, Friedman, Henry S, Brown, Michael C, He, Yiping, Sampson, John H, Bolognesi, Dani P., Friedman, Allan H, McLendon, Roger E., Herndon, James E., Randazzo, Dina, Nair, Smita K, McLendon, Roger E, Khasraw, Mustafa, Muscat, Andrea M, Muscat, Andrea M., Lipp, Eric S, Zhang, Gao, Nair, Smita K., Varn, Frederick S, Bolognesi, Dani P, Bigner, Darell D., McSherry, Frances, Friedman, Henry S., Lin, Xiang, Friedman, Allan H., Zhao, Junfei, Varn, Frederick S., Bigner, Darell D, Ashley, David M, Chen, Yeqing, Desjardins, Annick, Herndon, James E, Peters, Katherine B, Brown, Michael C., Ashley, David M., Hai Yan, John H. Sampson, Junfei Zhao, Yiping He, Smita K. Nair, Allan H. Friedman, Eric S. Lipp, Yeqing Chen, Dani P. Bolognesi, Zhi Wei, Nike Beaubier, Gao Zhang, Michael C. Brown, Roger E. McLendon, James E. Herndon, Roel G. Verhaak, Frances McSherry, Darell D. Bigner, Mustafa Khasraw, Katherine B. Peters, David M. Ashley, Frederick S. Varn, Dina Randazzo, Annick Desjardins, Henry S. Friedman, Xiang Lin, Matthias Gromeier, Andrea M. Muscat   +71 more
core   +2 more sources

The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker [PDF]

Cancer Cell, 2021
Tumor mutational burden (TMB) reflects cancer mutation quantity. Mutations are processed to neo-antigens and presented by major histocompatibility complex (MHC) proteins to T cells. To evade immune eradication, cancers exploit checkpoints that dampen T cell reactivity.
Denis L, Jardim, Aaron, Goodman, Debora, de Melo Gagliato, Razelle, Kurzrock   +3 more
openaire   +2 more sources

What is the burden of proof for tumor mutational burden in gliomas? [PDF]

Neuro-Oncology, 2020
Abstract The treatment of patients with a variety of solid tumors has benefitted from immune checkpoint inhibition targeting the anti-programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) axis. The US Food and Drug Administration (FDA) granted accelerated approval of PD-1 inhibitor, pembrolizumab, for the treatment of ...
Mustafa Khasraw, Kyle M Walsh, Amy B Heimberger, David M Ashley   +3 more
openaire   +2 more sources

Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors [PDF]

Cancer Discovery, 2020
Abstract Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase of interrogated genomic sequence, varies across malignancies. Panel sequencing–based estimates of TMB have largely replaced whole-exome sequencing–derived TMB in the clinic.
Dan Sha, Zhaohui Jin, Jan Budczies, Klaus Kluck, Albrecht Stenzinger, Frank A. Sinicrope   +5 more
openaire   +2 more sources